{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:19:25Z","timestamp":1783131565771,"version":"3.54.6"},"reference-count":70,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005623","name":"University of Tokushima","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005623","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21im0210116h0003"],"award-info":[{"award-number":["21im0210116h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19lm0203094h0001"],"award-info":[{"award-number":["19lm0203094h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17lm0203037h0001"],"award-info":[{"award-number":["17lm0203037h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17im0210605h0002"],"award-info":[{"award-number":["17im0210605h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xcrm.2026.102762","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:49:52Z","timestamp":1776869392000},"page":"102762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["AAV-based gene therapy with modified HEXB confers lasting therapeutic benefits in GM2 gangliosidosis models"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4852-1257","authenticated-orcid":false,"given":"Keisuke","family":"Kitakaze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiya","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nijiho","family":"Kamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Katakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sota","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Takino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2953-5530","authenticated-orcid":false,"given":"Kohji","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102762_bib1","doi-asserted-by":"crossref","first-page":"10195","DOI":"10.1523\/JNEUROSCI.0822-13.2013","article-title":"Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis","volume":"33","author":"Sandhoff","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.xcrm.2026.102762_bib2","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.3390\/ijms21176213","article-title":"GM2 gangliosidoses: Clinical features, pathophysiological aspects, and current therapies","volume":"21","author":"Leal","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102762_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2017.05.004","article-title":"Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives","volume":"118","author":"Solomon","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.xcrm.2026.102762_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/cne.10578","article-title":"Insulin-like growth factor-II\/mannose-6-phosphate receptor: Widespread distribution in neurons of the central nervous system including those expressing cholinergic phenotype","volume":"458","author":"Hawkes","year":"2003","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.xcrm.2026.102762_bib5","doi-asserted-by":"crossref","first-page":"15172","DOI":"10.1073\/pnas.0607053103","article-title":"Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors","volume":"103","author":"Sly","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102762_bib6","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"CLN2 Study Group, Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102762_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107709","article-title":"Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: Final report of 5-year results from a Japanese open-label phase 1\/2 study","volume":"140","author":"Seo","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.xcrm.2026.102762_bib8","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/jimd.12615","article-title":"Advances in therapies for neurological lysosomal storage disorders","volume":"46","author":"Ellison","year":"2023","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.xcrm.2026.102762_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1064924","article-title":"Gene therapy for lysosomal storage diseases: Current clinical trial prospects","volume":"14","author":"Kido","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.xcrm.2026.102762_bib10","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/ijms25021050","article-title":"Delivery of adeno-associated virus vectors to the central nervous system for correction of single gene disorders","volume":"25","author":"Daci","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102762_bib11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF00219337","article-title":"Quantitative correlation between the residual activity of \u03b2-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease","volume":"88","author":"Leinekugel","year":"1992","journal-title":"Hum. Genet."},{"key":"10.1016\/j.xcrm.2026.102762_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41591-021-01664-4","article-title":"AAV gene therapy for Tay-Sachs disease","volume":"28","author":"Flotte","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102762_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omtm.2018.10.011","article-title":"Efficacy of a bicistronic vector for correction of Sandhoff disease in a mouse model","volume":"12","author":"Woodley","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.102762_bib14","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ymthe.2020.06.021","article-title":"Pronounced therapeutic benefit of a single bidirectional AAV vector administered systemically in Sandhoff mice","volume":"28","author":"Lahey","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102762_bib15","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1038\/s41591-025-03822-4","article-title":"Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1\/2 trial","volume":"31","author":"Eichler","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102762_bib16","article-title":"Characterization of immune responses to rAAVrh8 gene therapy for GM2 gangliosidosis in phase 1\/2 trial","author":"Flotte","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.xcrm.2026.102762_bib17","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1172\/JCI85300","article-title":"Protease-resistant modified human \u03b2-hexosaminidase B ameliorates symptoms in GM2 gangliosidosis model","volume":"126","author":"Kitakaze","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102762_bib18","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/974819","article-title":"Systemic delivery of tyrosine-mutant AAV vectors results in robust transduction of neurons in adult mice","volume":"2013","author":"Iida","year":"2013","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.xcrm.2026.102762_bib19","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/jimd.12558","article-title":"Aberrant autophagy in lysosomal storage disorders marked by a lysosomal SNARE protein shortage due to suppression of endocytosis","volume":"45","author":"Tanaka","year":"2022","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.xcrm.2026.102762_bib20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng1095-170","article-title":"Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism","volume":"11","author":"Sango","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2026.102762_bib21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/ng1196-348","article-title":"Mice lacking both subunits of lysosomal \u03b2-hexosaminidase display gangliosidosis and mucopolysaccharidosis","volume":"14","author":"Sango","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2026.102762_bib22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/mt.2012.44","article-title":"Gene transfer corrects acute GM2 gangliosidosis\u2014potential therapeutic contribution of perivascular enzyme flow","volume":"20","author":"Cach\u00f3n-Gonz\u00e1lez","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102762_bib23","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/hmg\/ddt459","article-title":"Reversibility of neuropathology in Tay\u2013Sachs-related diseases","volume":"23","author":"Cach\u00f3n-Gonz\u00e1lez","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2026.102762_bib24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/hum.2020.175","article-title":"Gene therapy in a mouse model of Niemann-Pick disease type C1","volume":"32","author":"Kurokawa","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102762_bib25","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/j.1471-4159.2005.02986.x","article-title":"Specific induction of macrophage inflammatory protein 1-\u03b1 in glial cells of Sandhoff disease model mice associated with accumulation of N-acetylhexosaminyl glycoconjugates","volume":"92","author":"Tsuji","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.xcrm.2026.102762_bib26","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1111\/j.1471-4159.2005.03317.x","article-title":"Metabolic correction in microglia derived from Sandhoff disease model mice","volume":"94","author":"Tsuji","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.xcrm.2026.102762_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131704","article-title":"AAV vectors advance cardiac gene therapy while overcoming challenges","volume":"400","author":"Muramatsu","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.xcrm.2026.102762_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3457","article-title":"Early distribution of 18F-labeled AAV9 vectors in the cerebrospinal fluid after intracerebroventricular or intracisternal magna infusion in non-human primates","volume":"25","author":"Kumagai","year":"2023","journal-title":"J. Gene Med."},{"key":"10.1016\/j.xcrm.2026.102762_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s42826-019-0006-0","article-title":"Reference values of hematological and biochemical parameters in young-adult cynomolgus monkey (Macaca fascicularis) and rhesus monkey (Macaca mulatta) anesthetized with ketamine hydrochloride","volume":"35","author":"Koo","year":"2019","journal-title":"Lab. Anim. Res."},{"key":"10.1016\/j.xcrm.2026.102762_bib30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/ani13030445","article-title":"Reference intervals and percentiles for hematologic and serum biochemical values in captive bred rhesus (Macaca mulatta) and cynomolgus macaques (Macaca fascicularis)","volume":"13","author":"Bakker","year":"2023","journal-title":"Animals."},{"key":"10.1016\/j.xcrm.2026.102762_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101168","article-title":"Intrathecal delivery of a bicistronic AAV9 vector expressing \u03b2-hexosaminidase A corrects Sandhoff disease in a murine model: A dosage study","volume":"32","author":"Ryckman","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.102762_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.57","article-title":"Construction of a hybrid \u03b2-hexosaminidase subunit capable of forming stable homodimers that hydrolyze GM2 ganglioside in vivo","volume":"3","author":"Tropak","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.102762_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057908","article-title":"In cellulo examination of a beta-alpha hybrid construct of beta-hexosaminidase A subunits, reported to interact with the GM2 activator protein and hydrolyze GM2 ganglioside","volume":"8","author":"Sinici","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102762_bib34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102762_bib35","first-page":"S3","article-title":"Gene therapy for spinal muscular atrophy: An emerging treatment option for a devastating disease","volume":"24","author":"Rao","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.xcrm.2026.102762_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/jfb15060153","article-title":"Evidence of lysosomal \u03b2-hexosaminidase enzymatic activity associated with extracellular vesicles: Potential applications for the correction of Sandhoff disease","volume":"15","author":"Calzoni","year":"2024","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.xcrm.2026.102762_bib37","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102762_bib38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-025-04103-w","article-title":"Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial","volume":"32","author":"Proud","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102762_bib39","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41591-025-04119-2","article-title":"Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial","volume":"32","author":"Kwon","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102762_bib40","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1089\/hum.2016.109","article-title":"Direct intracranial injection of AAVrh8 encoding monkey \u03b2-N-acetylhexosaminidase causes neurotoxicity in the primate brain","volume":"28","author":"Golebiowski","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102762_bib41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2174\/1566523221666210916153051","article-title":"Treatment of GM2 gangliosidosis in adult Sandhoff mice using an intravenous self-complementary hexosaminidase vector","volume":"22","author":"Osmon","year":"2022","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102762_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/gim.2016.70","article-title":"Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy","volume":"19","author":"de Vries","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.xcrm.2026.102762_bib43","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nbt.1484","article-title":"Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment","volume":"26","author":"Wang","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102762_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109151","article-title":"Enzyme replacement therapy using a modified \u03b1-N-acetylgalactosaminidase to suppress progressive glycolipid accumulation and escape from antidrug antibody formation in young human NAGA-transgenic\/Gla-knockout mice","volume":"145","author":"Sakuraba","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.xcrm.2026.102762_bib45","series-title":"Immunogenicity Testing of Therapeutic Protein Products\u2014Developing and Validating Assays for Anti-drug Antibody Detection","year":"2019"},{"key":"10.1016\/j.xcrm.2026.102762_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101593","article-title":"Biodistribution of AAV1, AAV5, AAV9, and AAVDJ serotypes after intra-cisterna magna delivery in non-human primates","volume":"33","author":"Okai","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.102762_bib47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0009-8981(02)00002-5","article-title":"Tay-Sachs and Sandhoff diseases: enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards","volume":"318","author":"Chamoles","year":"2002","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.xcrm.2026.102762_bib48","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ymgme.2014.01.002","article-title":"Incidence and carrier frequency of Sandhoff disease in Saskatchewan determined using a novel substrate with detection by tandem mass spectrometry and molecular genetic analysis","volume":"111","author":"Fitterer","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.xcrm.2026.102762_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108517","article-title":"Tandem mass spectrometric enzyme assay for simultaneous detection of Tay-Sachs and Sandhoff diseases in dried blood spots for newborn screening","volume":"142","author":"Herbst","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.xcrm.2026.102762_bib50","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.expneurol.2014.09.020","article-title":"Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease","volume":"263","author":"Bradbury","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.xcrm.2026.102762_bib51","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1212\/WNL.0000000000008959","article-title":"Quantitative oculomotor and nonmotor assessments in late-onset GM2 gangliosidosis","volume":"94","author":"Stephen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.xcrm.2026.102762_bib52","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clinbiochem.2007.12.026","article-title":"Simultaneous quantification of GM1 and GM2 gangliosides by isotope dilution tandem mass spectrometry","volume":"41","author":"Gu","year":"2008","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.xcrm.2026.102762_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.106983","article-title":"Plasma GM2 ganglioside potential biomarker for diagnosis, prognosis and disease monitoring of GM2-Gangliosidosis","volume":"138","author":"Blondel","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.xcrm.2026.102762_bib54","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1007\/s00216-024-05487-3","article-title":"A multiplexed targeted method for profiling of serum gangliosides and glycosphingolipids: application to GM2-gangliosidosis","volume":"416","author":"Kim","year":"2024","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.xcrm.2026.102762_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029074","article-title":"Lyso-GM2 ganglioside: a possible biomarker of Tay-Sachs disease and Sandhoff disease","volume":"6","author":"Kodama","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102762_bib56","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ymgme.2014.11.015","article-title":"Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses","volume":"114","author":"Utz","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.xcrm.2026.102762_bib57","article-title":"Chitotriosidase as a biomarker for gangliosidoses","volume":"29","author":"Kim","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.xcrm.2026.102762_bib58","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41434-020-00203-z","article-title":"Intra-cisterna magna delivery of an AAV vector with the GLUT1 promoter in a pig recapitulates the physiological expression of SLC2A1","volume":"28","author":"Nakamura","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102762_bib59","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s43856-025-00841-7","article-title":"N-glycan-modified \u03b1-L-iduronidase produced by transgenic silkworms ameliorates clinical signs in a Japanese macaque with mucopolysaccharidosis I","volume":"5","author":"Shinoda","year":"2025","journal-title":"Commun. Med."},{"key":"10.1016\/j.xcrm.2026.102762_bib60","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1074\/jbc.273.1.66","article-title":"Specificity of mouse GM2 activator protein and \u03b2-N-acetylhexosaminidases A and B. Similarities and differences with their human counterparts in the catabolism of GM2","volume":"273","author":"Yuziuk","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.102762_bib61","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.expneurol.2017.09.012","article-title":"Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease","volume":"299","author":"Seyrantepe","year":"2018","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.xcrm.2026.102762_bib62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/TACG.S85354","article-title":"Animal models of GM2 gangliosidosis: utility and limitations","volume":"9","author":"Lawson","year":"2016","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.xcrm.2026.102762_bib63","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2021.08.009","article-title":"Natural history of Tay-Sachs disease in sheep","volume":"134","author":"Story","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.xcrm.2026.102762_bib64","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ymgme.2021.05.001","article-title":"A pathogenic HEXA missense variant in wild boars with Tay-Sachs disease","volume":"133","author":"Bertani","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.xcrm.2026.102762_bib65","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0304-4165(92)90168-T","article-title":"Generation of one set of monoclonal antibodies specific for a-pathway ganglio-series gangliosides","volume":"1117","author":"Kotani","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.xcrm.2026.102762_bib66","series-title":"Lipid Storage Disorders. NATO ASI Series","first-page":"237","article-title":"GM2-gangliosidosis: Bl variant with thermostable \u03b2-hexosaminidase A and molecular analysis of the mutant enzyme","author":"Izumi","year":"1988"},{"key":"10.1016\/j.xcrm.2026.102762_bib67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1034\/j.1600-0404.2002.01097.x","article-title":"Western blotting analysis of the \u03b2-hexosaminidase \u03b1- and \u03b2-subunits in cultured fibroblasts from cases of various forms of GM2 gangliosidosis","volume":"105","author":"Utsumi","year":"2002","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.xcrm.2026.102762_bib68","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neuro.2008.11.001","article-title":"Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research","volume":"30","author":"Cheung","year":"2009","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.xcrm.2026.102762_bib69","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/0076-6879(87)38063-2","article-title":"Enzymatic diagnosis of sphingolipidoses","volume":"138","author":"Suzuki","year":"1987","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.xcrm.2026.102762_bib70","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/13.5.355","article-title":"Histochemical demonstration of N-acetyl-\u03b2-glucosaminidase employing naphthol AS-BI N-acetyl-\u03b2-glucosaminide as substrate","volume":"13","author":"Hayashi","year":"1965","journal-title":"J. Histochem. Cytochem."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:36:48Z","timestamp":1783129008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126001795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666379126001795"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102762","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV-based gene therapy with modified HEXB confers lasting therapeutic benefits in GM2 gangliosidosis models","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102762"}}